Update in Treatment and Targets in Ewing Sarcoma
Update in Treatment and Targets in Ewing Sarcoma
复制标题
DOI：
10.1016/j.hoc.2013.07.001
复制
发表时间：
2013-10-01
影响因子：
2.4
通讯作者：
Choy, Edwin
中科院分区：
文献类型：
--
作者：
Cote, Gregory M.;Choy, Edwin
自从细胞毒性化疗的发展以来，局部和转移性尤因肉瘤患者预后的改善仍然是肿瘤学最深刻的进步之一，也是肉瘤研究人员最自豪的成就之一。寻找新的治疗方法的分子靶点已成为尤文氏肉瘤研究的热点。改进临床前尤文氏肉瘤模型和先进分子技术的发展将建立在了解EWS/FLI1功能、EWS/FLI1转录靶点和这些肿瘤中其他关键驱动事件的基础上。
The improvement in outcome for patients with localized and metastatic Ewing sarcoma since the development of cytotoxic chemotherapy remains one of the most profound advances in oncology and one of the proudest achievements of sarcoma researchers. Identification of molecular targets for new treatments has become an intense area within Ewing sarcoma research. The development of improved preclinical Ewing sarcoma models and advanced molecular techniques will build on knowledge of EWS/FLI1 function, EWS/FLI1 transcription targets, and the other critical driver events in these tumors.